Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Botulinum toxin associated with antidepressant effects across indications, injection sites

Publish date:: August 11, 2020

Key clinical point: Botulinum toxin may be an effective antidepressant independent of the indication it is being used for and the injection site.

Major finding: Injections of botulinum toxin for hyperhidrosis, facial wrinkles, migraine prophylaxis, spasticity, and spasms significantly reduced reports of depression and related adverse events, compared with a control group.

Study details: An analysis of 174,243 adverse event reports for botulinum toxin to the FDA between January 2004 and December 2019 and controls.

Disclosures: One author reports being a consultant for Allergan. Dr. Makunts and the other author report no relevant conflicts of interest.

Citation:

Makunts T et al. Sci Rep. 2020 Jul 30;10(1):12851. doi: 10.1038/s41598-020-69773-7.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

More severe AD correlates with worse sleep health and attention problems in children,

Shortcomings identified in study of acne videos on TikTok,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Must Reads in Aesthetic Dermatology

Novel botulinum toxin type A earns high marks for forehead lines,

Botulinum toxin associated with antidepressant effects across indications, injection sites,

Novel rapid acoustic pulse device shows promise for treating cellulite,

Microneedling plus 10% TCA peels bests CO2 laser alone for infraorbital dark circles,

Lasers Expunge Mucosal Tattoos,